How are MRK strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MRK strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 29.27%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$303.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a MRK strangle?

The breakeven for the MRK strangle priced on this page is roughly $102.97 and $120.03 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MRK market-implied 1-standard-deviation expected move is approximately 8.39%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current MRK implied volatility affect this strangle?

MRK ATM IV is at 29.27% with IV rank near 46.00%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

MRK Strangle Strategy

MRK (Merck & Co., Inc.), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NYSE.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV.

MRK (Merck & Co., Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $280.20B, a trailing P/E of 31.39, a beta of 0.20 versus the broader market, a 52-week range of 73.31-125.14, average daily share volume of 9.7M, a public-listing history dating back to 1978, approximately 73K full-time employees. These structural characteristics shape how MRK stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.20 indicates MRK has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. MRK pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a strangle on MRK?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current MRK snapshot

As of May 15, 2026, spot at $111.64, ATM IV 29.27%, IV rank 46.00%, expected move 8.39%. The strangle on MRK below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this strangle structure on MRK specifically: MRK IV at 29.27% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 8.39% (roughly $9.37 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MRK expiries trade a higher absolute premium for lower per-day decay. Position sizing on MRK should anchor to the underlying notional of $111.64 per share and to the trader's directional view on MRK stock.

MRK strangle setup

The MRK strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MRK near $111.64, the first option leg uses a $117.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MRK chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MRK shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$117.00	$1.55
Buy 1	Put	$106.00	$1.48

MRK strangle risk and reward

Net Premium / Debit: -$303.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$303.00
Breakeven(s): $102.97, $120.03
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

MRK strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on MRK. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$10,296.00
$24.69	-77.9%	+$7,827.69
$49.38	-55.8%	+$5,359.38
$74.06	-33.7%	+$2,891.07
$98.74	-11.6%	+$422.75
$123.43	+10.6%	+$339.56
$148.11	+32.7%	+$2,807.87
$172.79	+54.8%	+$5,276.18
$197.47	+76.9%	+$7,744.49
$222.16	+99.0%	+$10,212.80

When traders use strangle on MRK

Strangles on MRK are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MRK chain.

MRK thesis for this strangle

The market-implied 1-standard-deviation range for MRK extends from approximately $102.27 on the downside to $121.01 on the upside. A MRK long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current MRK IV rank near 46.00% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on MRK should anchor more to the directional view and the expected-move geometry. As a Healthcare name, MRK options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MRK-specific events.

MRK strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MRK positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MRK alongside the broader basket even when MRK-specific fundamentals are unchanged. Always rebuild the position from current MRK chain quotes before placing a trade.

Frequently asked questions

What is a strangle on MRK?: A strangle on MRK is the strangle strategy applied to MRK (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With MRK stock trading near $111.64, the strikes shown on this page are snapped to the nearest listed MRK chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are MRK strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MRK strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 29.27%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$303.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a MRK strangle?: The breakeven for the MRK strangle priced on this page is roughly $102.97 and $120.03 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MRK market-implied 1-standard-deviation expected move is approximately 8.39%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on MRK?: Strangles on MRK are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MRK chain.
How does current MRK implied volatility affect this strangle?: MRK ATM IV is at 29.27% with IV rank near 46.00%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.